Definium Therapeutics Sees Unusually High Options Volume (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the target of some unusual options trading activity on Thursday. Traders bought 16,346 call options on the stock. This represents an increase of approximately 342% compared to the typical volume of 3,697 call options.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DFTX shares. Canaccord Genuity Group set a $64.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 13th. Bank of America assumed coverage on shares of Definium Therapeutics in a report on Tuesday. They issued a “buy” rating and a $75.00 target price for the company. Maxim Group set a $55.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. Oppenheimer reiterated an “outperform” rating and set a $70.00 price objective on shares of Definium Therapeutics in a research note on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $63.00.

Definium Therapeutics Stock Down 3.1%

NASDAQ:DFTX traded down $1.40 during mid-day trading on Thursday, hitting $44.42. 524,620 shares of the company’s stock traded hands, compared to its average volume of 2,281,632. The company has a fifty day moving average of $41.19 and a 200 day moving average of $27.49. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70. The company has a market capitalization of $5.97 billion, a P/E ratio of -12.95 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, analysts forecast that Definium Therapeutics will post -2.92 EPS for the current year.

Insider Buying and Selling at Definium Therapeutics

In other news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 48,096 shares of company stock worth $2,165,763 over the last quarter. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada increased its holdings in shares of Definium Therapeutics by 10.4% during the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares in the last quarter. Creative Planning boosted its holdings in Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after buying an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock worth $315,000 after buying an additional 2,342 shares in the last quarter. Rhumbline Advisers grew its position in Definium Therapeutics by 6.3% during the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after buying an additional 6,839 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.